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Background & objectives: This study aims to determine the status of plasma estrogen, 
prolactin and thyroid stimulating hormone in schizophrenic patients with different age 
groups.  
Methods: A total of 60 schizophrenic patients of age group 18-65 years of both sexes 
from good socio-economic background were selected and the patients were divided into 
three groups based on age namely young, adult and elderly subjects. They all met DSM-
IV (Diagnostic and Statistical Manual of Mental Disorders-IV) criteria for schizophrenia. 
Sixty age and sex-matched healthy normal control subjects with no individual and 
familial history of mental illness were recruited to participate in this study (30 males and 
30 females). Fresh blood samples were collected and plasma was separated to measure 
the status of hormones by ECLIA method in the plasma of 60 schizophrenia subjects and 
60 healthy controls.  
Results: Results showed that plasma levels of hormones indicated abnormalities 
significantly among the different age groups. There is also significant difference in the 
levels of these hormones in the male and female subjects also. These data reveal that age 
and gender has influence on the levels of the hormonal status in schizophrenic patients.  
Interpretation & conclusion: Understanding these basic pathologic processes may yield 
novel targets and hormonal therapy for the development of more effective treatments foe 
the different age groups and male and female schizop renics. 
 
KEYWORDS: Schizophrenia, Symptoms, Estrogen, Prolactin, TSH, Abnormalities 
 
Introduction: 
Schizophrenia, one of the most debilitating and baffling mental illnesses, defines 
a group of disorders that cause distorted thought and perception. Thoughts can be 
scrambled or jump from subject to subject. Perception can be distorted beyond reality, 
causing people to hear or see things that are not there [1]. 
People with schizophrenia go through periods of getting better and worse – 
remission and relapse. They can go for long periods of time without any symptoms, but 
because schizophrenia is often a chronic illness it requires ongoing medical attention, like 
hypertension and diabetes [2]. 
Hormonal influences on the development of schizophrenia in both sexes were 
postulated. The new theory goes beyond serotonin and nor epinephrine, which are clearly 
involved in depression, to look at stress hormones.  Many people with mood problems 
have others in their family who also has mood problems; the same is true of anxiety 
Abstract 
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problems.   Stress hormones within the brain may be the basis for these lasting changes 
[3]. 
Some early psychiatrists already believed that schizophrenic disorders were 
associated with a disturbed balance of sexual hormones also. This belief was based on the 
observation of a. an insufficient functioning of the sexual glands with so-called 
hypoestrogenism, and b. an influence of ovarian function on schizophrenic psychoses. 
As the review of Riecher –Rossler, 2002 [4] showed there are findings from recent 
research that seem to confirm that estrogens may have a protective effect in 
schizophrenia). The estrogen hypothesis also posits that this hormone serves as a 
protective factor in the development of schizophrenia. 
Gender and age differences in patients with schizoprenia have been noted in 
studies of age at onset, symptoms, course of illness, and cognitive deficits. . Males are 
more prone to schizophrenia than females on average, women are diagnosed with 
schizophrenia 2 to 10 years later than men [5]. In addition to a delayed peak of onset of 
schizophrenia for women, some, but not all, investigators have found an additional 
smaller peak after ages 40 to 45, around the time of decreasing levels of estrogen [6]. The 
timing and gender specificity of this increased prevalence of schizophrenia have led some 
researchers to speculate that estrogen levels protect women from developing 
schizophrenia and that the drop in estrogen levels associated with menopause may put 
women at risk to develop schizophrenia later in life [7]. 
There are also occasional hints at a possible hypoestrogenism in schizophrenia.  
Riecher- Rössler, 2002 [7], by his own epidemiological, clinical and animal studies the 
hypothesis of a protective effect of oestrogens wasfor the first time systematically 
examined and confirmed. 
Highly elevated prolactin seemed to be an overwhelming aberration in 
schizophrenics. Enhanced prolactin levels in schizophrenic patients may be the results of 
anti-psychotic medication [8]. Nevertheless, prolactin abnormality was already described 
in un-medicated, drug-naive schizophrenics about one decade ago [9]. Hyperprolactin in 
schizophrenia is not an obligatory consequence of neuroleptic treatments. Apart from 
neuroleptic treatments, there are some other factors such as stress or cytokines (e.g. IFN- 
gamma and TNF-alpha ) that could have impacts on prlactin release. With the advent of 
prolactin sparing anti-psychotics, ample consideration needs to be given to the 
physiological consequences of hyperprolactinaemia in schizophrenic patients. 
The lifetime prevalence of depression in schizophrenia patients with TSH 
abnormalities is doubles that of the general population and has beenreported to reduce the 
efficacy of antidepressant treatment; it is associated with anxiety [10] and changes in 
mood and cognitive functioning. There is also evidence that exercise capa ity may be 
impaired due to significant reduction of exercise-related stroke volume, cardiac index, 
vital capacity and reduced anaerobic thresholds [11]. All these factors may affect 
subjective perception of health status of schizophrenics. 
Though there is accumulating evidence of altered hormonal status in 
schizophrenia, Studies of endocrine abnormalities in schizophrenia has produced the 
usual medley of conflicting results. In the present study, we investigated the effect of age 
and gender on the levels of these hormones in schizop renic patients and compared the 
levels of these hormones with controls. The present tudy was undertaken during the 
month of September 2004 to June 2007, in the Postgraduate and Research department of 
Online International Interdisciplinary Research Journal, {Bi-Monthly}, ISSN2249-9598, Volume-IV, Issue-III, May-June 2014  
 w w w . o i i r j . o r g                      I S S N  2 2 4 9- 9 5 9 8 
 
Page 30 
biochemistry, Dr. N.G.P Arts and Science College, with the collaboration of Kovai 
Medical Centre and Hospital (KMCH), a multispeciality hospital. 
 
Materials and Methods 
Patients: A total of 60 schizophrenic patients of age group 18-65 years of both sexes 
from good socio-economic background were selected from Udhayam Mananala 
kaapagam, a mental Health care center, Coimbatore, Tamilnadu, India. They all met 
DSM-IV (Diagnostic and Statistical Manual of Mental Disorders-IV) criteria (American 
Psychiatric Association, 2000) [12] for schizophrenia.  Schizophrenic subjects were 
divided into three groups i-e young, elderly and adult (1) Schizophrenics with age range 
between 15-30 years, (2) schizophrenics with age range between 31-45years, (2) 
schizophrenics with age range 46-65 years.  
Control: Sixty age and sex-matched healthy normal control subjects with no individual 
and familial history of mental illness were recruited to participate in this study. They 
included 30 males and 30 females. Their ages ranged from 15 to 65 years with mean age 
(28.9±14.1) years.  
Ethical Considerations: The design and the layout of this project was carried out with 
the approval the Chairman, Kovai Medical Center and Hospitals, and due permission was 
obtained from the board of institutional review Committee of the Kongu mananala 
Arakkattalai, before the start of the work. Informed and written consent was obtained 
from all subjects prior to examination. 
Assay of Hormones: The tests were performed at the biochemistry division of Diagnostic 
laboratory, Kovai Medical Center and Hospitals, Coimbatore. Blood was collected using 
standard methods as described by Varley, 1956, and plasma was separated. Hormones 
were measured by an electro-chemiluminescence immunoassay ‘ECLIA’ using Roche 
Elecsys E170 immunoassay nalyzers (Roche Diagnostics, UK). The Elecsys prolactin 
test had been calibrated against the 3rd IRP WHO Reference Standard 84/500. The 
Elecsys estrogen test had been calibrated via ID-GC\MS (isotope dilution – gas 
chromatography-mass spectrometry. The Elecsys TSH test had been calibrated against the 
2nd IRP WHO Reference Standard 80/558.  
 
Results and Discussion 
Results in Table 1 summarize all analyzed biochemical parameters. Table 1 shows 
significant decrease   in   estrogen levels in all the study groups compared to the control 
group. Within the control groups, people with age group of above 45 were facing more 
estrogen deficiency compared with the subjects who ere of below 45-age range ( 
p<0.01). Among schizophrenia patients, it was found that the estrogen levels decreased 
which is statistically significant in adult and eldrly schizophrenics ( p <0.001) compared 
with schizophrenic patients with age group of below 30. The Prolactin levels are very 
highly increased (p<0.001) in adult schizophrenic patients when compared to normal 
young and elderly subjects (Table 1). The prolactin levels are increased in normal adult 
group when compared to normal young and elderly subjects (p<0.01) where as it is 
highly increased in young and adult schizophrenics patients (p<0.001) when compared to 
the normal elderly controls (Table1). It is observed from the results that the level of TSH 
is increased significantly in all schizophrenic groups when compared with normal control 
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subjects. Results also showed that there was no sigificant decrease in the level of TSH 
among normal elderly subjects compared with normal young and adult control subjects. 
As far as gender concerned, we found significant difference in the tested 
parameters of estrogen between male and female subjcts in both schizophrenia and 
control groups. This hormone was highly deficient i males compared with females. 
However, there were significant differences among the study and control subjects with 
the same gender in some test parameters (Table 2). The levels of prolactin and TSH 
increased significantly in females compared with males of schizophrenia patients. In 
general, the level of TSH increased noticeably in schizophrenia patients compared with 
control groups. Also there is no notable difference between males and females of normal 
controls. 
                                                 Table 1                                                    
Circulatory levels of Estrogen, Prolactin and TSH in Young, Adult and Elderly 
subjects with schizophrenia and Healthy controls  
(Values are mean ± SD) Statistical comparison was done between: age-matched 
Controls and Schizophrenia subjects. 
a p<0.01, a* p<0.001; b p<0.01, b*<0.001 
a statistical comparison between age group < 30 and > 30 of control  vs 
schizophrenics.) 
b (statistical comparison of age group < 30 and > 30 among   schizophrenia 
patients. 
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 Table 2 
Circulatory levels of Estrogen, Prolactin and TSH levels of Control and 
Schizophrenia Male and Female subjects (Values are mean ± SD) 
 
 
Statistical comparison was done between gender matched Controls and Schizophrenics; 
a. Controls and Schizophrenics (male) ; b. Controls and Schizophrenics (female). c. male 
and females of schizophrenia patients .a,b,c , p<0.01. 
 
A growing body of research suggesting that es rogen has an important role in 
mental processes in normal women [13] as well as in women with Alzheimer’s disease 
[14] and other neuropsychiatric diseases such as schizophrenia [15]. 
Much remains to be learned about the complex interac ion among the hormonal 
status and schizophrenia. Many of the studies contain small samples, resulting in 
inconsistent findings regarding the effects of estrogen on the woman with schizophrenia. 
It is clear that there are gender differences in the age of onset and the presentation of 
schizophrenia. Estrogen appears to be related to psychopathology in the menstrual cycles 
of premenopausal women and in postpartum psychosis. 
Estrogen has been hypothesized to have a protective and antipsychotic-like effect 
in women at risk for schizophrenia [16]. In our result  we found that the estrogen levels 
decreased significantly in adult and elderly schizophrenic patients. It is also noticed from 
our results that normal and schizophrenia males are h ving very low levels of estrogen 
compared than that of normal and schizophrenic femal s.  
A study of hospitalized patients reported that when estrogen levels were rising, 
women with schizophrenia required lower doses of neuroleptics [17]. The therapeutic 
response, as measured by duration of hospitalization, amount of neuroleptics, and clinical 
status at discharge, was measured in 65 women with a diagnosis of schizophrenia and 35 
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women with a diagnosis of affective disorder. The women with sc izophrenia required 
lower doses of neuroleptic medication if they were admitted during phases of menstrual 
cycle when estrogen levels were low.  
Estrogen is postulated to exert a multimodal protectiv  effect on brain cells 18. 
When estrogen receptors are activated, the brain is roused and memory systems function 
more efficiently. Estrogen neutralizes the neurotoxic effects of a variety of stressors, thus 
explaining, perhaps, the later onset of schizophrenia symptoms in women when 
compared with men. Estrogen action on neurotransmitter systems may also explain why 
women respond to antipsychotics faster than men and at lower doses, and why side 
effects differ [15]. 
In terms of clinical outcomes, women with schizophrenia seem to fare better then 
men, but appear more vulnerable to psychotic illness in the period after birth and 
menopause. As these vulnerable periods to psychosis are associated with estrogen 
withdrawal, this hormone has been proposed as a treatment for schizophrenia.  
Clinical research results indicate that symptoms in women frequently vary with 
the menstrual cycle, worsening during low estrogen phases. Pregnancy is often, though 
not always, a less symptomatic time for women, but relapses are due to frequent 
postpartum. Some work suggests that in he younger age groups women require lower 
antipsychotic dosages than men but that following menopause they require higher 
dosages. Estrogen has been used effectively as an adju ctive treatment in women with 
schizophrenia. Estrogen may also play a preventive role in schizophrenia. These findings 
suggest that estrogen may provide valuable adjunctive therapy for women with psychosis.  
Prolactin has been found to stimulate proliferation of oligodendrocyte precursor 
cells. These cells differentiate into oligodendrocytes, the cells responsible for the 
formation of myelin coatings on axons in the central nervous system. In our study elderly 
patients and males have significantly increased levels of prolactin. Our results are 
confirmed and supported by the study of Alice Kuruvillaet al., 1992 [19]. Serum prolactin 
levels were measured in large cohorts of schizophrenic patients (67 males and 42 
females) and normal subjects (78 males and 42 females). Results showed that there was 
no significant difference between the serum prolactin levels of patients and controls, 
except in the age group 15–29 years. There were no significant differences between the 
serum prolactin levels of males and females, either among the patients or the control 
subjects.  The rise in serum prolactin levels after the commencement of neuroleptic 
medication in the patients was greater in females than in males even though the female 
patients received neuroleptics at lower doses.  
IFN gamma and TNF- alpha have the potential to act directly on anterior pituitary 
cells to slow the rate of prolactin release. The hyperprolactin in our patients could be 
partly due to decreased TNF-alpha and, particularly, IFN- gamma. But both IFN-gamma 
and TNF-alpha have no effect on the inhibition of prolactin release mediated by 
dopamine. The dopaminergic tuberoinfundibular pathwy is responsible for dopamine-
mediated prolactin release; this pathway is inhibited in acute stress, leading to increased 
prolactin levels [9,20]. 
The datas of Alice Kuruvilla indicate that serum prolactin levels in unmedicated 
males and females are similar; however, the prolactin response to neuroleptic medication 
is greater in females than in males. Present results also indicated that the levels of TSH 
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are also elevated significantly in schizophrenia patients especially females have elevated 
TSH levels so as we found many females were hypothyr id symptoms.  
Most pituitary hormone production is controlled by signals that come in the form 
of other hormones. That means the pituitary acts only when it receives a stimulating 
hormone message from elsewhere in the body. For example, when thyroid activity is low, 
the hypothalamus, a higher brain center, releases th  hormone TRH to stimulate the 
pituitary to release thyroid stimulating hormone (TSH).Surprisingly the hormone TRH, in 
addition to stimulating the pituitary release of TSH, also, triggers the release of prolactin.  
To synthesize these hormones, the thyroid gland requir s iodine, selenium, zinc, 
niacin, vitamin B12, lipoic acid, and the antioxidants vitamin C and E [21], who wisely 
included hypothyroidism as one of the causes of schizop renia. Many literatures indicate 
that the levels of these elements are low in schizop renia patients. Present findings 
indicated that schizophrenic patients should be examined for hypothyroidism. When there 
are clinical symptoms and signs of this condition, thyroid should be added to the 
program. 
Hypothalamus secretes dopamine which inhibits the release of prolactin. 
Dopamine travels from the hypothalamus to the pituitary in a small network of veins 
called a venous portal system. Anything that interferes with this fine network may 
prevent this inhibitory message from reaching the pituitary gland. The result is that the 
pituitary will produce too much prolactin. When the ypothalamus sees that the prolactin 
levels are too high, it manufactures more dopamine, trying to get prolactin levels back to 
normal. Unfortunately, if the message doesn’t get through, the pituitary continues to 
produce and release prolactin. 
In conclusion, hormones are playing a vital role in the disease progression of 
schizophrenia. Also the influences of these hormones vary based on gender and age 
groups. Our data, as well as those of other investigators, suggest a significantly later age 
at onset of schizophrenia in women than in men. There is somewhat more direct evidence 
from animal studies indicating that estrogen modulates dopamine systems in a manner 
similar to neuroleptics, although there are some inconsistencies in the literature. Few 
studies have examined the effects of estrogen administration in conjunction with 
neuroleptics on psychotic symptoms. The relations between schizop renia hormonal 
influence-role of age, gender underline the clinical nterest of our study. But these results 
need to be confirmed by further studies by taking larger number samples and further 
advanced techniques should be adopted to make sure of th current results. 
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